Editas Medicine, Inc. EDIT
We are a pioneering gene editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M | $13.7M | $6.1M |
| R&D | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M | $158.0M | $96.9M | $90.7M | $83.2M | $57.0M |
| SG&A | $49.9M | $72.0M | $69.7M | $70.7M | $76.2M | $67.6M | $64.6M | $55.0M | $50.5M | $46.3M |
| Total operating expenses | $200.5M | $283.5M | $247.3M | $245.7M | $218.7M | $225.6M | $161.5M | $145.7M | $133.7M | $103.2M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M | -$134.8M | -$140.9M | -$113.7M | -$119.9M | -$97.2M |
| Interest expense | $2.1M | $0 | — | — | — | — | — | — | — | — |
| Pre-tax income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M | -$116.0M | -$133.7M | -$110.0M | -$120.3M | -$97.2M |
| EPS, basic | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | — | — | — |
| EPS, diluted | -1.80 | -2.88 | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 | -2.33 | -2.98 | -3.02 |
| Shares, diluted (wtd. avg.) | $88.7M | $82.3M | $76.0M | $68.7M | $67.6M | $58.6M | $50.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $146.6M | $131.5M | $127.5M | $141.5M | $207.4M | $143.6M | $239.8M | $136.4M | $148.2M | $186.9M |
| Short-term investments | $0 | $138.4M | $199.5M | $202.8M | $296.3M | $262.4M | $219.0M | $234.2M | $182.5M | — |
| Receivables | $15.2M | $16.3M | $10.2M | $5.1M | $267.0K | $6.0M | $418.0K | $30.0K | $679.0K | $88.0K |
| Total current assets | $163.9M | $289.3M | $340.8M | $356.8M | $507.3M | $419.1M | $463.8M | $374.8M | $332.2M | $187.2M |
| Property, plant and equipment | $3.5M | $14.5M | $12.0M | $15.6M | $17.1M | $14.0M | $10.9M | $40.2M | $39.4M | $40.4M |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M | $572.6M | $508.9M | $420.4M | $373.3M | $229.2M |
| Accounts payable | $2.6M | $5.5M | $8.3M | $9.5M | $5.0M | $6.4M | $5.8M | $5.3M | $4.0M | $4.6M |
| Short-term debt | $5.0M | $5.0M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $46.2M | $77.2M | $63.2M | $60.1M | $46.9M | $58.2M | $60.0M | $35.9M | $36.7M | $33.1M |
| Long-term debt | $53.6M | $52.4M | $0 | — | — | — | — | — | — | — |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M | $179.0M | $246.4M | $184.2M | $165.2M | $94.6M |
| Retained earnings | -$1.63B | -$1.47B | -$1.23B | -$1.08B | -$857.7M | -$665.2M | -$549.2M | -$416.3M | -$305.9M | -$185.5M |
| Total equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M | $393.6M | $262.4M | $236.2M | $208.1M | $134.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M | -$179.8M | -$40.7M | -$45.7M | -$9.4M | -$50.2M |
| Depreciation and amortisation | $5.3M | $5.8M | $6.1M | $6.3M | $5.1M | $4.0M | $2.8M | $3.3M | $2.7M | $1.2M |
| Stock-based compensation | $10.0M | $21.4M | $19.8M | $29.3M | $43.4M | $23.2M | $27.2M | $26.6M | $23.4M | $16.9M |
| Capital expenditure | $607.0K | $8.8M | $4.7M | $4.1M | $8.0M | $7.2M | $6.2M | $4.8M | $2.1M | $3.5M |
| Investing cash flow | $138.7M | $162.1M | -$3.7M | $114.1M | -$54.5M | -$140.5M | $12.3M | -$53.1M | -$183.8M | -$3.5M |
| Financing cash flow | $40.5M | $56.0M | $118.0M | $1.3M | $282.1M | $224.1M | $131.8M | $86.9M | $154.5M | $97.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001650664-26-000037.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |